Investors Face 1bn Precipice on Fixed Rate Bonds

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Investors Face £1bn Precipice on Fixed Rate Bonds

LONDON, UNITED KINGDOM--(Marketwired - July 18, 2013) - New analysis from HSBC reveals that fixed rate bond holders face a substantial savings precipice this year when they come to reinvest. Rates have fallen significantly - up to 2.47% on some products - and left savers with the prospect of a far lower income from their investments once their current deals have matured.

Bruno Genovese, Head of Savings at HSBC, comments:

"As an increase in interest rates continues to look further into the distance, the knock on downward pressure being applied to saving rates is affecting the incomes of investors.

"Many savers value the guaranteed income and security offered by fixed rate products. However, those who want to reinvest their savings from matured fixed rate products into comparable deals this year may find that their income drops significantly. Savers need to consider all available options and this may not be to simply reinvest their savings in a similar product.

"Diversifying savings portfolios to have a variety of products can ensure that investors lessen the impact of falling interest rates. At HSBC, we can offer a range of options which offer a more stable way to invest for long-term growth."

Almost 5.3 million fixed rate products worth nearly £93 billion will mature in 2013, with the largest number due to mature in November (568,455). Of these products, 2.8 million have matured over the last six months, but the recent fall in rates means bondholders face a £1 billion fall in income if they reinvest their savings pot into similar products (see table 1).

Table 1: Savings Precipice Overview (previous six months)
Investment Period No. of products matured Total Investment Total change in return if reinvested in same fixed term today
6 month 70,957 £2,483,037,724 -£2,076,026
1 year 1,349,591 £22,498,036,989 -£203,124,423
18 months 188,559 £5,019,324,501 -£78,128,458
2 years 454,902 £10,520,285,067 -£297,819,265
3 years 267,306 £5,949,408,915 -£341,848,655
4 years 12,212 £268,382,235 -£9,810,562
5 Years 419,600 £845,032,596 -£86,317,378
TOTAL 2,763,127 £47,583,508,027 -£1,019,124,766

Total Income Falls

All fixed rate products have been affected by the drop in rates and now offer lower returns if savers were to reinvest their money into the best-buy products currently available (see table 2). However, the biggest falls in income will be felt by 3, 5 and 2 year bond holders with drops of 52%, 50% and 45% respectively. Last year, holders of 1 year and 18 month bonds saw a slight rise in income, however even these product holders can now expect a fall in income of 39% and 38% respectively.

The smallest fall in income will be felt by 6 month bond holders, but, at 12% this drop will still have a significant impact.

Table 2: Individual Investors Savings Precipice (previous six months)
Investment Period Average Investment* Average Return** Average change in potential income over investment period Percentage change in potential income over investment period
6 month £34,994 £229 -£28 -12%
1 year £16,670 £478 -£184 -39%
18 Months £26,619 £1,217 -£463 -38%
2 years £23,126 £1,789 -£814 -45%
3 years £22,257 £3,027 -£1,570 -52%
4 years £21,977 £2,958 -£970 -33%
5 Years £2,014 £497 -£249 -50%

* = For fixed rate investments maturing in 2012 ** = Based on Best Buy rates in month of investment

Individual Investor Falls

As well as the biggest drop in overall income, holders of 3 year bonds will suffer the biggest drop in individual income. The average investment in these bonds currently stands at £22,333 and if this were to be reinvested in the current best-buy products on offer, investors can expect a return of £3,037 - a fall of £1,576 compared to their last investment in 3 year bonds.

Fall in AERs

The fall in income across all fixed rate products is a result of a drop in average best-buy AERs available. The falls vary from 0.16% for 6 month bonds to 2.47% for 5 year bonds (see Table 3). Despite longer term bonds suffering the biggest falls in AERs, these products still offer higher rates than the shorter term investment options.

Table 3: Average Difference in AERs
Investment Period Average change in Best Buy Rate
6 month -0.16%
1 year -1.11%
18 Months -1.16%
2 years -1.76%
3 years -2.35%
4 years -1.10%
5 Years -2.47%

For those investors in the 3.1 million fixed rate products due to mature over the remainder of 2013 - particularly those 2, 3 and 5 year bonds in July and November ( see graph below ) - HSBC recommends that people seriously consider what the best possible home for their savings is.

Notes to Editors
Table 4: Total number of fixed rate products maturing in 2013 (February to December inclusive).
Investment Period No. Products Total Investment
6 month 70,961 £2,483,107,385
1 year 2,499,576 £43,221,331,947
18 Months 359,960 £10,380,802,627
2 years 982,269 £23,979,087,225
3 years 489,574 £10,131,420,790
4 years 30,998 £689,832,578
5 Years 851,796 £1,920,987,361
TOTAL 5,285,134 £92,806,569,913

For more information visit: http://www.hsbc.co.uk/1/2/savings-accounts

HSBC Bank plc: HSBC serves 16.1 million customers in the UK and employs approximately 52,000 people. In the UK, HSBC offers a complete range of personal, premier and private banking services including bank accounts and mortgages. It also provides commercial banking for small to medium businesses and corporate and institutional banking services. HSBC Bank plc is a wholly owned subsidiary of HSBC Holdings plc.

The HSBC Group: HSBC Holdings plc, the parent company of the HSBC Group, is headquartered in London. The Group serves customers worldwide from around 7,500 offices in over 80 countries and territories in Europe, the Asia-Pacific region, North and Latin America, and the Middle East and Africa. With assets of US$2,556bn at 31 December 2011, HSBC is one of the world's largest banking and financial services organisations.

HSBC Suman Hughes 020 7992 2748 suman.hughes@hsbc.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 50

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 145

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 25

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 159

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 83

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 155

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 10

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 19

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 101

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 104

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading

Top 5 Most Recently Viewed Articles

Volta Finance Limited: Monthly Insights and Performance Metrics

Updated Category News Views 252

Understanding Volta Finance Limited's Performance for September 2025 Volta Finance Limited (VTA / VTAS) recently released its monthly report for September 2025. This report sheds light on the performance metrics that have shaped the company's strategies and outcomes over the past month, illustrating how they navigate an ever-changing financial landscape. Performance...

Continue Reading
Class Actions Alert: Understanding Investor Rights for SOC, LMT, NVO, LINE

Updated Category News Views 213

Understanding Class Action Lawsuits for Shareholders In today’s fast-paced investment world, shareholders must stay informed about class action lawsuits that may affect their investments. A recent alert highlights key class actions involving four publicly-traded companies, offering investors a glimpse into their rights and potential next steps. Sable Offshore Corp....

Continue Reading
Exploring ONCT-534: New Insights on Advanced Prostate Cancer

Updated Category News Views 202

Recent Updates on ONCT-534 for Advanced Prostate Cancer Oncternal Therapeutics, Inc. (NASDAQ: ONCT) has unveiled encouraging updates regarding its investigational therapy, ONCT-534, specifically targeting relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC). This exciting development stems from the company’s ongoing Phase 1/2 Study, known as...

Continue Reading
GDS Holdings Celebrates Successful IPO of C-REIT in Shanghai

Updated Category News Views 197

GDS Holdings Completes C-REIT IPO on Shanghai Stock Exchange Shanghai, China — GDS Holdings Limited (NASDAQ: GDS; HKEX: 9698), a prominent developer and operator of high-performance data centers, has recently triumphantly finished its initial public offering (IPO) for the China REIT (C-REIT) on the Shanghai Stock Exchange. This achievement marks a significant milestone...

Continue Reading
Surge in Russian Stocks: MOEX Russia Index Reaches New Heights

Updated Category News Views 255

Russian Stocks Experience Notable Gains In recent trading sessions, Russian stocks showed significant upward movement, showcasing the resilience of various sectors within the economy. With the MOEX Russia Index closing higher, this is an indication of investor optimism and market recovery. Key Contributors to Market Gains Sector Performance Highlights The increase in the...

Continue Reading